Regenerative Medicine of Articular Cartilage: Characterization and Comparison of Chondrogenic Potential and Immunomodulatory Adult Mesenchymal Stem Cells

Articular cartilage can be the seat of many diseases including osteoarthritis and traumatic defaults. The cartilage has no intrinsic ability to repair resulting at long term in function loss in the joints. Currently available treatments are not satisfactory in the long term, the use of mesenchymal stem cells appears to be promising due to their ability to multipotency and immunomodulation properties. This project aims to determine the most appropriate source for regenerative medicine of cartilage stem cells from tissue taken during arthroplasty in patients with osteoarthritis. These cells will be tested for different chondrogenic markers. The success of this project will consider the implementation of a strategy for regenerative medicine in bone and joint diseases.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Knee Osteoarthritis Arthritis Joint Diseases Musculoskeletal Diseases Osteoarthritis Osteoarthritis, Knee Rheumatic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Nantes University Hospital

Nantes, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients aged over 18 years
Patients with knee osteoarthritis
Patients requiring total knee arthroplasty
Patients who signed the consent form

Exclusion criteria

Patients aged less than 18 years
Major Patients under guardianship
Pregnant woman
Infectious pathology or progressive tumor
Refusal to participate in the study
State of immunosuppression
Congenital or acquired malformation resulting in a deformation of the knee

Treatment and study plan

Arthroplasty

Procedure

Blood, bone marrow, synovial fluid and Hoffa's fat pad samplings

Primary outcomes

Increased expression of chondrogenic markers

Time frame: up to 3 years

Increased expression of chondrogenic markers will be Evaluated by different techniques:

in vitro: Histology fit for chondrogenic markers, RT-PCR on the following markers aggrecan, type II collagen, Sox9, Comp, type IX collagen

in vivo: In a second step, differentiated MSCs are implanted in vivo after combination with a hydrogel subcutaneously in nude mice. The formation of a neo cartilage tissue will be assessed by histology for type II collagen and aggrecan

Secondary outcomes

Increasing secretion of anti-inflammatory molecules in vitro

Time frame: up to 3 years

Increasing secretion of anti-inflammatory molecules in vitro will be tested by several techniques:

Microfluidic cards (TLDA assays) for the analysis of the expression of genes involved in inflammation and in the secretion of anti-inflammatory molecules Inhibition of proliferation of autologous T cells activated or not Assay for anti-inflammatory and pro-inflammatory molecules Analysis of the expression of surface markers by flow cytometry

Sponsors and collaborators

Lead sponsor

Nantes University Hospital

Other

Registry information

Acronym: ARTHROSTEM

Important dates

Study start: 2015
Primary completion: 2016
Study completion: 2016
First posted: Jun 17, 2013
Registry last updated: Feb 17, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed